{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:19:42Z","timestamp":1777551582012,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) substantially contributes to poor functional outcomes, loss in productivity, and poor health-related quality of life (HRQoL). Despite the existence of various scales, there is a notable gap in existing HRQoL reviews with regard to the availability of Arabic validated scales. As a response to this gap, the aim of our scoping review is to identify validated scales, focusing on their psychometric validation procedures, to contribute valuable insights to the understanding of HRQoL among the Arabic-speaking people with PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A scoping review was conducted at the end of December 2022, using the Medline and Embase databases. The focus of this review was on examining the psychometric properties and validation procedures of included scales. Articles were included in the full-text screening process if they focused on people with PD of any age, included a scale measuring HRQoL in Arabic, and were written in English, French, or Arabic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After applying inclusion\/exclusion criteria, 10 studies were selected to analyze HRQoL scales validated in people with PD. However, the PDQ-39 is the only HRQol PD specific scales validated in the Arabic language. Five studies validated in people with PD were identified in the context of instrument validation (3 generic, 1 specific validated in 2 studies).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There are several HRQoL measurement scales for people with PD. However, only one specific HRQoL instrument has been validated in Arabic for people with PD. For the remaining instruments identified they were just used in people with PD without being validated in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-20002-0","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T13:01:52Z","timestamp":1726318912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychometric properties of Arabic-translated-related quality of life scales for people with parkinson disease: a scoping review"],"prefix":"10.1186","volume":"24","author":[{"given":"Chiraz","family":"Azaiez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Chalghaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amayra","family":"Tannoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noomen","family":"Guelmami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medina","family":"Srem-Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Quansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Elvis","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heifa","family":"Sneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"Boussayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Ghalmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazin Inhaier","family":"Lami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Mandigout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choukri ben","family":"Ayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fairouz","family":"Azaiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"issue":"8","key":"20002_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna). 2017;124(8):901\u20135.","journal-title":"J Neural Transm (Vienna)"},{"issue":"9423","key":"20002_CR2","first-page":"1783","volume":"363","author":"A Samii","year":"2004","unstructured":"Samii A, Nutt JG, Ransom BR. Parkinson\u2019s Disease Lancet. 2004;363(9423):1783\u201393.","journal-title":"Parkinson\u2019s Disease Lancet"},{"key":"20002_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis. 2018;4:21.","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"20002_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000110316","volume":"12","author":"S al Rajeh","year":"1993","unstructured":"al Rajeh S, et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology. 1993;12(3):164\u201378.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"20002_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0303-8467(86)80005-1","volume":"88","author":"PP Ashok","year":"1986","unstructured":"Ashok PP, et al. Epidemiology of Parkinson\u2019s disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986;88(2):109\u201313.","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"20002_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000110330","volume":"12","author":"N Attia Romdhane","year":"1993","unstructured":"Attia Romdhane N, et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993;12(5):285\u201399.","journal-title":"Neuroepidemiology"},{"issue":"9","key":"20002_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/mds.22041","volume":"23","author":"HT Benamer","year":"2008","unstructured":"Benamer HT, et al. Parkinson\u2019s disease in arabs: a systematic review. Mov Disord. 2008;23(9):1205\u201310.","journal-title":"Mov Disord"},{"issue":"1","key":"20002_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12889-023-15018-x","volume":"23","author":"S Safiri","year":"2023","unstructured":"Safiri S, et al. The burden of Parkinson\u2019s disease in the Middle East and North Africa region, 1990\u20132019: results from the global burden of disease study 2019. BMC Public Health. 2023;23(1):107.","journal-title":"BMC Public Health"},{"issue":"6 Suppl 1","key":"20002_CR9","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1097\/NRL.0b013e31823966b4","volume":"17","author":"PJ Garcia Ruiz","year":"2011","unstructured":"Garcia Ruiz PJ, Catal\u00e1n MJ, Fern\u00e1ndez JM, Carril. Initial motor symptoms of Parkinson disease. Neurologist. 2011;17(6 Suppl 1):S18\u201320.","journal-title":"Neurologist"},{"issue":"Suppl 3","key":"20002_CR10","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1353-8020(09)70770-9","volume":"15","author":"E Wolters","year":"2009","unstructured":"Wolters E. Non-motor extranigral signs and symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S6\u201312.","journal-title":"Parkinsonism Relat Disord"},{"issue":"0 3","key":"20002_CR11","first-page":"S42","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(0 3):S42\u201380.","journal-title":"Mov Disord"},{"issue":"2","key":"20002_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"2","key":"20002_CR13","first-page":"e13275","volume":"13","author":"M Kumaresan","year":"2021","unstructured":"Kumaresan M, Khan S. Spectrum of non-motor symptoms in Parkinson\u2019s Disease. Cureus. 2021;13(2):e13275.","journal-title":"Cureus"},{"key":"20002_CR14","doi-asserted-by":"crossref","unstructured":"Perlmutter JS. Assessment of Parkinson disease manifestations. Curr Protoc Neurosci 2009 Chapter 10: p. Unit10.1.","DOI":"10.1002\/0471142301.ns1001s49"},{"key":"20002_CR15","doi-asserted-by":"crossref","unstructured":"V\u00e1radi C. Clinical Features of Parkinson\u2019s Disease: The Evolution of Critical Symptoms. Biology (Basel), 2020. 9(5).","DOI":"10.3390\/biology9050103"},{"issue":"16","key":"20002_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"P Rizek","year":"2016","unstructured":"Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157\u201365.","journal-title":"CMAJ"},{"issue":"22","key":"20002_CR17","doi-asserted-by":"publisher","first-page":"e2106","DOI":"10.1212\/WNL.0000000000006565","volume":"91","author":"S Karceski","year":"2018","unstructured":"Karceski S. Parkinson disease and mortality. Neurology. 2018;91(22):e2106\u20138.","journal-title":"Neurology"},{"issue":"1","key":"20002_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41531-022-00320-z","volume":"8","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez MC, et al. Parkinson\u2019s disease clinical milestones and mortality. Npj Parkinson\u2019s Disease. 2022;8(1):58.","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"20002_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14802\/jmd.20034","volume":"14","author":"PC Poortvliet","year":"2021","unstructured":"Poortvliet PC, et al. The Queensland Parkinson\u2019s project: an overview of 20 years of mortality from Parkinson\u2019s disease. J Mov Disorders. 2021;14(1):34.","journal-title":"J Mov Disorders"},{"issue":"13","key":"20002_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/mds.25898","volume":"29","author":"AD Macleod","year":"2014","unstructured":"Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615\u201322.","journal-title":"Mov Disord"},{"issue":"1","key":"20002_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.parkreldis.2007.05.005","volume":"14","author":"J Marinus","year":"2008","unstructured":"Marinus J, et al. Evaluation of the Dutch version of the Parkinson\u2019s Disease Questionnaire 39. Parkinsonism Relat Disord. 2008;14(1):24\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"20002_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline EM, et al. Genetic and Environmental Factors in Parkinson\u2019s Disease Converge on Immune function and inflammation. Mov Disord. 2021;36(1):25\u201336.","journal-title":"Mov Disord"},{"issue":"6","key":"20002_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson Disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"issue":"6","key":"20002_CR24","first-page":"573","volume":"34","author":"L Cuenca","year":"2019","unstructured":"Cuenca L, et al. Parkinson\u2019s disease: a short story of 200 years. Histol Histopathol. 2019;34(6):573\u201391.","journal-title":"Histol Histopathol"},{"issue":"2","key":"20002_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020;21(2):103\u201315.","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"20002_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jagp.2019.03.002","volume":"27","author":"D Weintraub","year":"2019","unstructured":"Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: a perfect storm. Am J Geriatr Psychiatry. 2019;27(9):998\u20131018.","journal-title":"Am J Geriatr Psychiatry"},{"key":"20002_CR27","doi-asserted-by":"crossref","unstructured":"Hoseinipalangi Z et al. A global systematic review and meta-analysis of the quality of life of patients with Parkinson\u2019s disease. East Mediterr Health J, 2023. 29.","DOI":"10.26719\/emhj.23.013"},{"key":"20002_CR28","unstructured":"European Medicines. Agency. Committee for Medicinal Products for Human use (CHMP): \u201eReflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 27 July 2005 [Last accessed 29 January 2013]. Available from: https:\/\/www.ispor.org\/workpaper\/research_practices\/proconcepts_definitions.pdf."},{"key":"20002_CR29","unstructured":"U.S Department of Health and Human Services Food and Drug Administration Guidance for Industry: \u201ePatient-Reported Outcome Measures. Use in Medical Product Development to Support Labeling Claims.December 2009 [Last accessed 29 January 2013]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf."},{"issue":"4","key":"20002_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/2168479014567322","volume":"49","author":"D Sawicki-Wrzask","year":"2015","unstructured":"Sawicki-Wrzask D, Thomsen M, Bjerrum OJ. An analysis of the fixed-dose combinations authorized by the European Union, 2009\u20132014: a Focus on Benefit-Risk and Clinical Development conditions. Ther Innov Regul Sci. 2015;49(4):553\u20139.","journal-title":"Ther Innov Regul Sci"},{"key":"20002_CR31","unstructured":"Schipper H. Clinch, JJ, Olweny CLM (1996) Quality of life studies: definitions and conceptual issues, In Spilker B, editor Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers:Philadelphia. PP 11\u201323."},{"key":"20002_CR32","unstructured":"International Society for Quality of Life Research (ISOQOL).health related of quality of life research. Available in: http:\/\/www.isoqol.org\/about-isoqol\/what-is-health-related-quality-of-life-research"},{"key":"20002_CR33","first-page":"11","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"H Schipper","year":"1996","unstructured":"Schipper H, Olweny CJ. Quality of life studies: definitions and conceptual issues. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. pp. 11\u201323."},{"issue":"11","key":"20002_CR34","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s11136-022-03187-y","volume":"31","author":"I Sanchez-Luengos","year":"2022","unstructured":"Sanchez-Luengos I, et al. Predictors of health-related quality of life in Parkinson\u2019s disease: the impact of overlap between health-related quality of life and clinical measures. Qual Life Res. 2022;31(11):3241\u201352.","journal-title":"Qual Life Res"},{"key":"20002_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/4681251","volume":"2021","author":"MC Portillo","year":"2021","unstructured":"Portillo MC, Haahr A, Navarta-S\u00e1nchez MV. Management, levels of support, quality of life, and social inclusion in Parkinson\u2019s Disease: interventions, innovation, and practice development. Parkinson\u2019s Disease. 2021;2021:1\u20134.","journal-title":"Parkinson\u2019s Disease"},{"key":"20002_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2019.08.016","volume":"121","author":"A Bottomley","year":"2019","unstructured":"Bottomley A, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:55\u201363.","journal-title":"Eur J Cancer"},{"issue":"7","key":"20002_CR37","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1007\/s00415-022-10969-4","volume":"269","author":"L van den Heuvel","year":"2022","unstructured":"van den Heuvel L, et al. Personalizing decision-making for persons with Parkinson\u2019s disease: where do we stand and what to improve? J Neurol. 2022;269(7):3569\u201378.","journal-title":"J Neurol"},{"issue":"12","key":"20002_CR38","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.sapharm.2020.01.018","volume":"16","author":"DM Dawoud","year":"2020","unstructured":"Dawoud DM, et al. Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in arabic-speaking countries. Res Social Adm Pharm. 2020;16(12):1754\u20139.","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"20002_CR39","doi-asserted-by":"publisher","first-page":"e2219","DOI":"10.1097\/GOX.0000000000002219","volume":"7","author":"L Nair","year":"2019","unstructured":"Nair L, Adetayo OA. Cultural competence and Ethnic Diversity in Healthcare. Plast Reconstr Surg Glob Open. 2019;7(5):e2219.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"1","key":"20002_CR40","doi-asserted-by":"publisher","first-page":"160940691774970","DOI":"10.1177\/1609406917749702","volume":"17","author":"R Pelzang","year":"2018","unstructured":"Pelzang R, Hutchinson AM. Establishing Cultural Integrity in qualitative research: reflections from a cross-cultural study. Int J Qualitative Methods. 2018;17(1):1609406917749702.","journal-title":"Int J Qualitative Methods"},{"issue":"1","key":"20002_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11136-012-0129-3","volume":"22","author":"F Al Sayah","year":"2013","unstructured":"Al Sayah F, et al. Health related quality of life measures in Arabic speaking populations: a systematic review on cross-cultural adaptation and measurement properties. Qual Life Res. 2013;22(1):213\u201329.","journal-title":"Qual Life Res"},{"issue":"13","key":"20002_CR42","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, et al. Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2011;26(13):2371\u201380.","journal-title":"Mov Disord"},{"issue":"1","key":"20002_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14737167.2021.1841638","volume":"21","author":"A Berardi","year":"2021","unstructured":"Berardi A, et al. Tools to assess the quality of life in patients with Parkinson\u2019s disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):55\u201368.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"20002_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"20002_CR45","doi-asserted-by":"crossref","unstructured":"Gazzard G et al. A scoping review of quality of life questionnaires in Glaucoma patients. J Glaucoma, 2021. 30(8).","DOI":"10.1097\/IJG.0000000000001889"},{"issue":"4","key":"20002_CR46","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/0256-4947.55313","volume":"29","author":"S Aburuz","year":"2009","unstructured":"Aburuz S, et al. The validity and reliability of the arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med. 2009;29(4):304\u20138.","journal-title":"Ann Saudi Med"},{"issue":"10","key":"20002_CR47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.26719\/emhj.19.041","volume":"25","author":"N El Osta","year":"2019","unstructured":"El Osta N, et al. Validation of the arabic version of the SF-36, generic questionnaire of quality of life related to health among the elderly in Lebanon. East Mediterr Health J. 2019;25(10):706\u201314.","journal-title":"East Mediterr Health J"},{"issue":"6","key":"20002_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.rehab.2012.05.003","volume":"55","author":"M Guermazi","year":"2012","unstructured":"Guermazi M, et al. Translation in Arabic, adaptation and validation of the SF-36 Health Survey for use in Tunisia. Ann Phys Rehabil Med. 2012;55(6):388\u2013403.","journal-title":"Ann Phys Rehabil Med"},{"key":"20002_CR49","doi-asserted-by":"crossref","unstructured":"Kharroubi SA et al. Examining the feasibility and acceptability of valuing the Arabic Version of SF-6D in a Lebanese Population. Int J Environ Res Public Health, 2020. 17(3).","DOI":"10.3390\/ijerph17031037"},{"issue":"1","key":"20002_CR50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12955-019-1249-z","volume":"17","author":"S Khoshhal","year":"2019","unstructured":"Khoshhal S, et al. Assessment of quality of life among parents of children with congenital heart disease using WHOQOL-BREF: a cross-sectional study from Northwest Saudi Arabia. Health Qual Life Outcomes. 2019;17(1):183.","journal-title":"Health Qual Life Outcomes"},{"key":"20002_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fneur.2018.00357","volume":"9","author":"AS Shalash","year":"2018","unstructured":"Shalash AS, et al. Non-motor symptoms as predictors of quality of life in Egyptian patients with Parkinson\u2019s Disease: a cross-sectional study using a culturally adapted 39-Item Parkinson\u2019s Disease Questionnaire. Front Neurol. 2018;9:357.","journal-title":"Front Neurol"},{"key":"20002_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5604\/01.3001.0013.9739","volume":"18","author":"TM Ahmadou","year":"2020","unstructured":"Ahmadou TM, et al. Assessment of the quality of life in Moroccan Parkinson\u2019s patients. Acta Neuropsychologica. 2020;18:67\u201376.","journal-title":"Acta Neuropsychologica"},{"issue":"3","key":"20002_CR53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00005650-199803000-00018","volume":"36","author":"SJ Coons","year":"1998","unstructured":"Coons SJ, et al. Reliability of an arabic version of the RAND-36 Health Survey and its equivalence to the US-English version. Med Care. 1998;36(3):428\u201332.","journal-title":"Med Care"},{"issue":"2","key":"20002_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/0256-4947.51790","volume":"29","author":"JU Ohaeri","year":"2009","unstructured":"Ohaeri JU, Awadalla AW. The reliability and validity of the short version of the WHO Quality of Life Instrument in an arab general population. Ann Saudi Med. 2009;29(2):98\u2013104.","journal-title":"Ann Saudi Med"},{"issue":"1","key":"20002_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41687-020-00233-6","volume":"4","author":"A AboAbat","year":"2020","unstructured":"AboAbat A, et al. Psychometric validation of a Saudi Arabian version of the sf-36v2 health survey and norm data for Saudi Arabia. J Patient-Reported Outcomes. 2020;4(1):67.","journal-title":"J Patient-Reported Outcomes"},{"key":"20002_CR56","first-page":"133","volume":"22","author":"L Emrani","year":"2016","unstructured":"Emrani L, Senhaji M, Bendriss A. Measuring health-related quality of life in the population of Tetouan, Morocco, by the SF-36: normative data and the influence of gender and age. East Mediterranean Health J = La Revue De sant\u00e9 De La M\u00e9diterran\u00e9e Orientale = al-Majallah al-\u1e63i\u1e25\u1e25\u012byah li-sharq al-mutawassi\u1e6d. 2016;22:133\u201341.","journal-title":"East Mediterranean Health J = La Revue De sant\u00e9 De La M\u00e9diterran\u00e9e Orientale = al-Majallah al-\u1e63i\u1e25\u1e25\u012byah li-sharq al-mutawassi\u1e6d"},{"key":"20002_CR57","doi-asserted-by":"crossref","unstructured":"Shalash AS, et al. Clinical Profile of Non-motor symptoms in patients with essential tremor: impact on quality of life and age-related differences. Tremor Other Hyperkinet Mov (N Y); 2019. p. 9.","DOI":"10.5334\/tohm.471"},{"key":"20002_CR58","unstructured":"Elagib MAA, Hamid OEA. The Health-related Quality of Life of Sudanese Patients with Idiopathic Parkinson\u2019s Disease. 2020."},{"issue":"2","key":"20002_CR59","first-page":"16","volume":"12","author":"AM Bekairy","year":"2018","unstructured":"Bekairy AM, et al. Validity and reliability of the arabic version of the the EuroQOL (EQ-5D). A study from Saudi Arabia. Int J Health Sci (Qassim). 2018;12(2):16\u201320.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"1","key":"20002_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s41983-020-00253-5","volume":"56","author":"EM Khedr","year":"2020","unstructured":"Khedr EM, et al. Depression and anxiety among patients with Parkinson\u2019s disease: frequency, risk factors, and impact on quality of life. Egypt J Neurol Psychiatry Neurosurg. 2020;56(1):116.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"2","key":"20002_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/jnnp.72.2.241","volume":"72","author":"J Marinus","year":"2002","unstructured":"Marinus J, et al. Health related quality of life in Parkinson\u2019s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002;72(2):241\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"20002_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res. 1995;4(3):241\u20138.","journal-title":"Qual Life Res"},{"issue":"5","key":"20002_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, et al. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26(5):353\u20137.","journal-title":"Age Ageing"},{"issue":"1","key":"20002_CR64","first-page":"41","volume":"158","author":"P Auquier","year":"2002","unstructured":"Auquier P, et al. [Validation of the French language version of the Parkinson\u2019s Disease Questionnaire - PDQ-39]. Rev Neurol (Paris). 2002;158(1):41\u201350.","journal-title":"Rev Neurol (Paris)"},{"issue":"7","key":"20002_CR65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/mds.10438","volume":"18","author":"P Hagell","year":"2003","unstructured":"Hagell P, et al. Health status measurement in Parkinson\u2019s disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003;18(7):773\u201383.","journal-title":"Mov Disord"},{"issue":"2","key":"20002_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4236\/ojmp.2014.32017","volume":"3","author":"V Murthy","year":"2014","unstructured":"Murthy V. Cadi-Soussi N. Patient reported Outcomes instruments in Schizophrenia: a review of Psychometric Properties. Open J Med Psychol. 2014;3(2):141\u201356. Toumi M.","journal-title":"Open J Med Psychol"},{"key":"20002_CR67","unstructured":"Storf M. The impact of FDA and EMA guidances regarding patient reported outcomes (PRO) on the drug development and approval process. Scientific examination work to obtain the title Master. of Drug Regulatory Affairs; 2013."},{"issue":"1","key":"20002_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-016-1428-x","volume":"26","author":"Y Xin","year":"2017","unstructured":"Xin Y, McIntosh E. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson\u2019s: a systematic review. Qual Life Res. 2017;26(1):1\u201323.","journal-title":"Qual Life Res"},{"issue":"9","key":"20002_CR69","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0895-4356(03)00148-3","volume":"56","author":"C Jenkinson","year":"2003","unstructured":"Jenkinson C, et al. Cross-cultural evaluation of the Parkinson\u2019s Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol. 2003;56(9):843\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"20002_CR70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1023\/A:1008979705027","volume":"8","author":"DM Bushnell","year":"1999","unstructured":"Bushnell DM, Martin ML. Quality of life and Parkinson\u2019s disease: translation and validation of the US Parkinson\u2019s Disease Questionnaire (PDQ-39). Qual Life Res. 1999;8(4):345\u201350.","journal-title":"Qual Life Res"},{"issue":"4","key":"20002_CR71","first-page":"159","volume":"14","author":"P Mart\u00ednez Mart\u00edn","year":"1999","unstructured":"Mart\u00ednez Mart\u00edn P, et al. The PDQ-39 Spanish version: reliability and correlation with the short-form health survey (SF-36). Neurologia. 1999;14(4):159\u201363.","journal-title":"Neurologia"},{"issue":"1","key":"20002_CR72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/mds.21216","volume":"22","author":"FJ Carod-Artal","year":"2007","unstructured":"Carod-Artal FJ, Martinez-Martin P, Vargas AP. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord. 2007;22(1):91\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"20002_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s41687-020-00248-z","volume":"4","author":"S McKown","year":"2020","unstructured":"McKown S, et al. Good practices for the translation, cultural adaptation, and linguistic validation of clinician-reported outcome, observer-reported outcome, and performance outcome measures. J Patient Rep Outcomes. 2020;4(1):89.","journal-title":"J Patient Rep Outcomes"},{"issue":"1\u20133","key":"20002_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.schres.2015.09.001","volume":"169","author":"JM Haro","year":"2015","unstructured":"Haro JM, et al. Understanding the impact of persistent symptoms in schizophrenia: cross-sectional findings from the Pattern study. Schizophr Res. 2015;169(1\u20133):234\u201340.","journal-title":"Schizophr Res"},{"issue":"2","key":"20002_CR75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/schbul\/sbq104","volume":"37","author":"JJ Blanchard","year":"2011","unstructured":"Blanchard JJ, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2):291\u20139.","journal-title":"Schizophr Bull"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-20002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-20002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T05:02:37Z","timestamp":1726376557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-20002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["20002"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-20002-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2505"}}